Problem Identification: Identifying people with hematologic cancer who are at risk of deteriorating and dying is essential to enable open, honest discussions, leading to appropriate decision making and effective end-of-life care.
Synthesis:
Twelve studies were included. The majority of studies (n = 8) sampled patients from palliative populations, and most were retrospective (n = 11). A number of signs, symptoms, and characteristics associated with end of life in people with a hematolgic malignancy were identified, including pain, hematopoietic dysfunction, dyspnea, and reduced oral intake.
Conclusions:
The studies described a clinical scenario of deterioration, largely in a palliative population. Findings indicate that people with a hematologic malignancy share certain clinical signs of deterioration with other populations and receive a high level of medical interventions at the end of life.
Implications for Practice: Nurses are well positioned to identify many of the signs, symptoms, and characteristics found in this review and can play a key role in identifying when a person is nearing the end of life. H ematologic malignancies include leukemia, lymphoma, multiple myeloma, myeloproliferative neoplasms, and myelodysplastic syndromes (Swerdlow et al., 2008) . These malignancies differ from solid tumors, most notably in the involvement of the bone marrow, leading to issues such as bleeding, infection, and anemia (Pallister & Watson, 2011) . The clinical course and prognosis for people with a hematologic malignancy vary significantly depending on many factors, including the type and specific subtype of the disease, response to treatment, and personal characteristics of the patient (Hung et al., 2013; Pallister & Watson, 2011) . Certain diseases, such as acute leukemia, advance rapidly and are imminently fatal (Pallister & Watson, 2011) , whereas other malignancies, such as low-grade lymphoma, often follow an indolent illness trajectory (Matasar & Zelenetz, 2008) . Aggressive treatment often holds dual potential for cure and mortality (Ezzone & Schmit-Pokorny, 2007) .
The illness trajectory of a person with a hematologic malignancy differs from that of a person with solid tumors (Auret, Bulsara, & Joske, 2003; Maddocks, Bentley, & Sheedy, 1994) and shares more similarities with the illness trajectory of a person with organ failure (i.e., heart and lung failure) in the context of
